home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 11/01/22

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic

ATLANTA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announc...
ALIM - Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences ( NASDAQ: ALIM ) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provid...

ALIM - Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments

ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...

ALIM - Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces t...
ALIM - Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences ( NASDAQ: ALIM ) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health ...

ALIM - Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces ...

ALIM - Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
ALIM - Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced to...

ALIM - Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences ( NASDAQ: ALIM ) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and He...

ALIM - Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to...
Previous 10 Next 10